BioSante Pharma Completes Enrollment in Pivotal LibiGel Trials – Video

Posted by Dr. Michael White, Published on November 2nd, 2012
()


BioSante Pharma Completes Enrollment in Pivotal LibiGel Trials
BioSante Pharmaceuticals (BPAX) announced today that enrollment of subjects in the second of two pivotal Phase III safety and efficacy trials for LibiGel, a testosterone gel being developed to treat female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, has been completed. Enrollment in the first efficacy trial was completed in February. The trials are being conducted under an FDA-approved special protocol assessment (SPA) agreement.From:TradeTheTrendViews:144 0ratingsTime:00:34More inNews Politics

Read the original here:

BioSante Pharma Completes Enrollment in Pivotal LibiGel Trials - Video

Contact Us Today


Name (*):

Email (*):

Phone (*):

Program (*):

State (*):

Age (30+ only):

(*) - Required



testosterone gel generic specialist.webp


Related Post

How useful was this post?

Click on a smiley face to rate it!

Average rating / 5. Vote count:

No votes so far! Be the first to rate this post.

Word Count: 105

Comments are closed.



what are normal levels by testosterone chart age.webp
testosterone testing.webp
enanthate vs cypionate